APA (7th ed.) Citation

Zheng, Y., Lu, X., Dong, H., Li, J., Shen, Y., Liu, Z., & Cui, H. (2025). Efficacy and safety of furmonertinib in patients with EGFR‑mutant advanced lung adenocarcinoma after failure of multiple lines of therapy: A single‑center retrospective study. Oncology Letters, 30(1), N.PAG. https://doi.org/10.3892/ol.2025.15074

Chicago Style (17th ed.) Citation

Zheng, Yumin, Xingyu Lu, Huijing Dong, Jia Li, Yulei Shen, Zhening Liu, and Huijuan Cui. "Efficacy and Safety of Furmonertinib in Patients with EGFR‑mutant Advanced Lung Adenocarcinoma After Failure of Multiple Lines of Therapy: A Single‑center Retrospective Study." Oncology Letters 30, no. 1 (2025): N.PAG. https://doi.org/10.3892/ol.2025.15074.

MLA (9th ed.) Citation

Zheng, Yumin, et al. "Efficacy and Safety of Furmonertinib in Patients with EGFR‑mutant Advanced Lung Adenocarcinoma After Failure of Multiple Lines of Therapy: A Single‑center Retrospective Study." Oncology Letters, vol. 30, no. 1, 2025, p. N.PAG, https://doi.org/10.3892/ol.2025.15074.